Abstract
The purpose of this qualitative study is to elucidate stakeholder perceptions of, and institutional practices related to cell-based therapies and products (CTP) regulation and commercialization in Canada. The development of reproducible, safe and effective CTPs is predicated on regulatory and commercialization environments that enable innovation. Manufacturing processes constitute a critical step for CTP development in this regard. The road from CTP manufacturing to translation in the clinic, however, has yet to be paved. This study aims to fill an empirical gap in the literature by exploring how CTP manufacturing facilities navigate Canadian regulatory and commercialization environments, which together drive the translation of novel CTPs from bench to bedside. Using the multi-level model of practice-driven institutional change proposed by Smets et al., we demonstrate how CTP manufacturing practices are governed by established standards, yet meaningfully shape higher-order regulatory and commercial norms in CTP research and development. We identify four key themes that undergird such processes of innovation: 1) managing regulatory uncertainty, which stems from an inability to classify CTPs within existing regulatory categories for approval and commercialization purposes; 2) building a ‘business case’ whereby a CTP's market potential is determined in large part by proving its safety and effectiveness; 3) standardizing manufacturing procedures that mobilize CTPs from a research and development phase to a commercialization one; and 4) networking between researchers and regulators to develop responsible commercialization processes that reflect the uniqueness of CTPs as distinct from other biologics and medical devices.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 27-39 |
| Number of pages | 13 |
| Journal | Applied and Translational Genomics |
| Volume | 11 |
| DOIs | |
| State | Published - Dec 1 2016 |
Fingerprint
Keywords
- Canada
- Cell-based therapies
- Commercialization
- Institutional change
- Regenerative medicine
- Regulation
ASJC Scopus subject areas
- Biotechnology
- Molecular Biology
- Pharmaceutical Science
Cite this
Uncertainty and innovation : Understanding the role of cell-based manufacturing facilities in shaping regulatory and commercialization environments. / Isasi, Rosario; Rahimzadeh, Vasiliki; Charlebois, Kathleen.
In: Applied and Translational Genomics, Vol. 11, 01.12.2016, p. 27-39.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Uncertainty and innovation
T2 - Understanding the role of cell-based manufacturing facilities in shaping regulatory and commercialization environments
AU - Isasi, Rosario
AU - Rahimzadeh, Vasiliki
AU - Charlebois, Kathleen
PY - 2016/12/1
Y1 - 2016/12/1
N2 - The purpose of this qualitative study is to elucidate stakeholder perceptions of, and institutional practices related to cell-based therapies and products (CTP) regulation and commercialization in Canada. The development of reproducible, safe and effective CTPs is predicated on regulatory and commercialization environments that enable innovation. Manufacturing processes constitute a critical step for CTP development in this regard. The road from CTP manufacturing to translation in the clinic, however, has yet to be paved. This study aims to fill an empirical gap in the literature by exploring how CTP manufacturing facilities navigate Canadian regulatory and commercialization environments, which together drive the translation of novel CTPs from bench to bedside. Using the multi-level model of practice-driven institutional change proposed by Smets et al., we demonstrate how CTP manufacturing practices are governed by established standards, yet meaningfully shape higher-order regulatory and commercial norms in CTP research and development. We identify four key themes that undergird such processes of innovation: 1) managing regulatory uncertainty, which stems from an inability to classify CTPs within existing regulatory categories for approval and commercialization purposes; 2) building a ‘business case’ whereby a CTP's market potential is determined in large part by proving its safety and effectiveness; 3) standardizing manufacturing procedures that mobilize CTPs from a research and development phase to a commercialization one; and 4) networking between researchers and regulators to develop responsible commercialization processes that reflect the uniqueness of CTPs as distinct from other biologics and medical devices.
AB - The purpose of this qualitative study is to elucidate stakeholder perceptions of, and institutional practices related to cell-based therapies and products (CTP) regulation and commercialization in Canada. The development of reproducible, safe and effective CTPs is predicated on regulatory and commercialization environments that enable innovation. Manufacturing processes constitute a critical step for CTP development in this regard. The road from CTP manufacturing to translation in the clinic, however, has yet to be paved. This study aims to fill an empirical gap in the literature by exploring how CTP manufacturing facilities navigate Canadian regulatory and commercialization environments, which together drive the translation of novel CTPs from bench to bedside. Using the multi-level model of practice-driven institutional change proposed by Smets et al., we demonstrate how CTP manufacturing practices are governed by established standards, yet meaningfully shape higher-order regulatory and commercial norms in CTP research and development. We identify four key themes that undergird such processes of innovation: 1) managing regulatory uncertainty, which stems from an inability to classify CTPs within existing regulatory categories for approval and commercialization purposes; 2) building a ‘business case’ whereby a CTP's market potential is determined in large part by proving its safety and effectiveness; 3) standardizing manufacturing procedures that mobilize CTPs from a research and development phase to a commercialization one; and 4) networking between researchers and regulators to develop responsible commercialization processes that reflect the uniqueness of CTPs as distinct from other biologics and medical devices.
KW - Canada
KW - Cell-based therapies
KW - Commercialization
KW - Institutional change
KW - Regenerative medicine
KW - Regulation
UR - http://www.scopus.com/inward/record.url?scp=85006342011&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85006342011&partnerID=8YFLogxK
U2 - 10.1016/j.atg.2016.11.001
DO - 10.1016/j.atg.2016.11.001
M3 - Article
AN - SCOPUS:85006342011
VL - 11
SP - 27
EP - 39
JO - Applied and Translational Genomics
JF - Applied and Translational Genomics
SN - 2212-0661
ER -